<DOC>
	<DOC>NCT00568737</DOC>
	<brief_summary>Adult Patients with Severe Sepsis</brief_summary>
	<brief_title>The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death</brief_title>
	<detailed_description>Compared with placebo, drotrecogin alfa (activated) reduces 28-day all-cause mortality in adult patients with severe sepsis at low risk of death (for example, with an Acute Physiology and Chronic Health Evaluation II (APACHE II) score &lt;25 or single organ dysfunction).</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Drotrecogin alfa activated</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<criteria>Adult patients with recent onset of severe sepsis or presence of a suspected or proven infection, and at least one induced organ dysfunction. Are indicated for the treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country. Are contraindicated for treatment with drotrecogin alfa (activated) under the applicable label in the investigative site country. Platelet count less than 30,000/mm3.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Severe Sepsis</keyword>
</DOC>